Novo Nordisk cuts Wegovy costs through subscription model
Novo Nordisk has launched what it describes as the first multi-month subscription programme for an FDA-approved obesity drug in the United States, targeting the self-pay market as it works to recover lost ground against Eli Lilly in the GLP-1 category.
Patients who pay without insurance coverage can save up to $1,200 per year on the Wegovy injection and up to $600 per year on the oral pill version, according to figures the Danish drugmaker provided. The programme is structured around multi-month purchasing commitments rather than single-fill prescriptions.
The initiative has a distribution element as well: Novo Nordisk confirmed that its FDA-approved GLP-1 therapies are now available through Hims & Hers, extending the programme's reach into one of the more active telehealth channels for weight-loss drugs.
The pricing move reflects the pressure Novo Nordisk faces from two directions. Eli Lilly's tirzepatide (Zepbound) has gained significant commercial traction, while compounding pharmacies and telehealth platforms have been selling cheaper alternatives to branded semaglutide, a market that regulators have moved to curtail but which has nonetheless conditioned patients to expect lower price points.
By locking self-pay patients into a subscription arrangement at a meaningful discount, Novo is attempting to combine affordability with the brand assurance of an FDA-approved product, a distinction the company has emphasised as it pushes back against compounded versions of semaglutide.
